Regulation of Cell Death and Inflammation by ISG15 during SARS-CoV2 Infection
SARS-CoV2 感染期间 ISG15 对细胞死亡和炎症的调节
基本信息
- 批准号:10287787
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-08 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAdult Respiratory Distress SyndromeAffectAgeAnimal ModelApoptosisAvian InfluenzaCOVID-19COVID-19 patientCRISPR screenCaspaseCell DeathCellsCessation of lifeClinical ResearchCohort AnalysisComplexCoronavirusDataDevelopmentDiseaseElderlyEpithelial CellsEvaluationFunctional disorderFutureGoalsHMGB1 ProteinHistologicHistopathologyHumanISG15 geneImmune responseIn VitroInfectionInflammationInflammatoryInflammatory ResponseInflammatory Response PathwayInterferonsKnockout MiceLungMachine LearningMapsMolecularMorbidity - disease rateMusPathogenesisPathologyPathway interactionsPatientsPatternPlayPopulationProductionProteinsPulmonary InflammationRIPK3 geneRegulationRespiratory FailureRoleSARS-CoV-2 infectionSevere Acute Respiratory SyndromeSourceStructure of respiratory epitheliumSymptomsTestingTracheal EpitheliumTropismUbiquitin Like ProteinsViralViral Load resultViral ProteinsViral Respiratory Tract InfectionVirusVirus DiseasesVirus ReplicationWorkagedbasebiomarker identificationcell typechemokinecytokinecytokine release syndromediagnostic biomarkergenome-widehigh risk populationhuman coronavirusin vivoinsightmortalitynovelolder patientpandemic diseasesevere COVID-19systemic inflammatory responsetherapeutic developmenttherapeutically effective
项目摘要
SARS-CoV2 is a highly contagious, novel human coronavirus that causes coronavirus disease
2019 (COVID-19). Currently over 7.4 million people in the US have confirmed infection with
SARS-CoV2 and over 215,000 have died. Severe COVID-19 is characterized by pulmonary and
systemic inflammation and multi-organ dysfunction, which disproportionally affects elderly
patients. The mechanism by which SARS-CoV2 triggers such severe pathogenesis is poorly
understood. Recent clinical studies have suggested that cell death, especially the induction of
necroptosis, may be predictor of severe COVID-19 disease. The mechanism by which the host
restricts necroptosis is unclear. In the preliminary data we have shown that the interferon induced
protein, ISG15, acts as a negative regulator of necroptosis and its downstream inflammatory
responses during viral infection. In this proposal we will test the hypothesis that SARS-CoV2
induces necroptosis and that ISG15 functions as a negative regulator of necroptosis in respiratory
epithelial cells. We will use in vitro primary tracheal epithelial cultures (hTECs) and an in vivo
mouse adapted SARS-CoV2 animal model to ask several questions including: 1) Does SARS-
CoV2 induce necroptosis in respiratory epithelial cells; 2) Does ISG15 modulate necroptotic cell
death as well as proinflammatory cytokine/chemokine production in respiratory epithelial cells
during SARS-CoV2 infection?; 3) Does necroptosis and its regulation by ISG15 contribute to
SARS-CoV2 pathogenesis? Overall, our studies will provide important insight into the
pathogenesis of SARS-CoV2 infection and provide potential insight into mechanisms underlying
severe disease, which may direct efforts toward the development of diagnostic markers and future
countermeasures.
SARS-COV2是一种高度传染性的新型人冠状病毒,引起冠状病毒病
2019(Covid-19)。目前,美国已有740万人确认感染
SARS-COV2和超过215,000人死亡。严重的Covid-19的特征是肺和
系统性炎症和多器官功能障碍,对老年人的影响不成比例
患者。 SARS-COV2触发如此严重的发病机理的机制很差
理解。最近的临床研究表明,细胞死亡,尤其是诱导
坏死性,可能是严重Covid-19疾病的预测指标。主机的机制
限制坏死性尚不清楚。在初步数据中,我们表明干扰素诱导
蛋白质(ISG15)充当坏死剂及其下游炎症的负调节剂
病毒感染期间的反应。在此提案中,我们将测试SARS-COV2的假设
诱导坏死性,ISG15在呼吸道中起坏死性的负调节剂
上皮细胞。我们将使用体外原发性气管上皮培养(HTEC)和体内
小鼠改编的SARS-COV2动物模型提出了几个问题,包括:1)SARS-
COV2在呼吸性上皮细胞中诱导坏死; 2)iSG15调节坏死细胞
呼吸性上皮细胞中的死亡以及促炎性细胞因子/趋化因子的产生
在SARS-COV2感染期间? 3)死坏死及其对ISG15的调节有助于
SARS-COV2发病机理?总体而言,我们的研究将为您提供重要的见解
SARS-COV2感染的发病机理,并提供对机制的潜在洞察力
严重的疾病,这可能会导致诊断标记和未来发展的努力
对策。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Deborah J Lenschow其他文献
Deborah J Lenschow的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Deborah J Lenschow', 18)}}的其他基金
Mechanistic characterization of SARS-CoV2 associated kidney injury
SARS-CoV2相关肾损伤的机制特征
- 批准号:
10319713 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Mechanistic characterization of SARS-CoV2 associated kidney injury
SARS-CoV2相关肾损伤的机制特征
- 批准号:
10427448 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Mechanistic characterization of SARS-CoV2 associated kidney injury
SARS-CoV2相关肾损伤的机制特征
- 批准号:
10619568 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Regulation of Cell Death and Inflammation by ISG15 during SARS-CoV2 Infection
SARS-CoV2 感染期间 ISG15 对细胞死亡和炎症的调节
- 批准号:
10424558 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
- 批准号:
10472003 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
- 批准号:
9764270 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
- 批准号:
10019327 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
- 批准号:
10251236 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Washington University Rheumatic Diseases Research Resource-based Center
华盛顿大学风湿病研究资源中心
- 批准号:
10704273 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
REGULATION OF INFLUENZA VIRUS INFECTION BY ISG15
ISG15 对流感病毒感染的监管
- 批准号:
8109260 - 财政年份:2009
- 资助金额:
$ 19.69万 - 项目类别:
相似国自然基金
肺撞击伤的生物力学机理及其并发ARDS的病理机制研究
- 批准号:39370670
- 批准年份:1993
- 资助金额:5.3 万元
- 项目类别:面上项目
刺激性气体致成人呼吸窘迫综合征的机理及诊断防治研究
- 批准号:39270582
- 批准年份:1992
- 资助金额:4.0 万元
- 项目类别:面上项目
相似海外基金
Elucidating the role of SERINC5 in SARS-CoV-2 infection
阐明 SERINC5 在 SARS-CoV-2 感染中的作用
- 批准号:
10624238 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Elucidating the role of SERINC5 in SARS-CoV-2 infection
阐明 SERINC5 在 SARS-CoV-2 感染中的作用
- 批准号:
10372283 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Targeting polyamines to suppress SARS-CoV-2 related disease
靶向多胺抑制 SARS-CoV-2 相关疾病
- 批准号:
10202992 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19
SARS-CoV-2 骨髓细胞受体作为 COVID-19 免疫致病机制的功能特征
- 批准号:
10288857 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Covid-19: Fast-tracking treatment by exploiting the steroid hormone receptor/TMPRSS2 axis
Covid-19:利用类固醇激素受体/TMPRSS2 轴进行快速治疗
- 批准号:
10153099 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别: